Legal & General Group
CSTL icon

Legal & General Group’s Castle Biosciences CSTL Stock Holding History

Legal & General Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$569K Sell
23,184
-6,551
-22% -$215K ﹤0.01% 2324
2025
Q4 		$1.16M Sell
29,735
-5,173
-15% -$167K ﹤0.01% 2175
2025
Q3 		$795K Hold
34,908
– – ﹤0.01% 2302
2025
Q2 		$713K Buy
34,908
+8,992
+35% +$166K ﹤0.01% 2335
2025
Q1 		$519K Sell
25,916
-36
-0.1% -$891 ﹤0.01% 2386
2024
Q4 		$692K Sell
25,952
-3,168
-11% -$96.5K ﹤0.01% 2352
2024
Q3 		$831K Buy
29,120
+4,730
+19% +$120K ﹤0.01% 2294
2024
Q2 		$531K Sell
24,390
-381
-2% -$8.49K ﹤0.01% 2404
2024
Q1 		$549K Sell
24,771
-50
-0.2% -$1.09K ﹤0.01% 2388
2023
Q4 		$536K Buy
24,821
+4,457
+22% +$78.4K ﹤0.01% 2420
2023
Q3 		$344K Sell
20,364
-245
-1% -$4.29K ﹤0.01% 2577
2023
Q2 		$283K Buy
20,609
+10,115
+96% +$205K ﹤0.01% 2650
2023
Q1 		$238K Buy
10,494
+674
+7% +$16.5K ﹤0.01% 2523
2022
Q4 		$231K Hold
9,820
– – ﹤0.01% 2552
2022
Q3 		$257K Buy
9,820
+707
+8% +$19.8K ﹤0.01% 2530
2022
Q2 		$200K Sell
9,113
-94
-1% -$2.18K ﹤0.01% 2635
2022
Q1 		$413K Buy
9,207
+223
+2% +$9.21K ﹤0.01% 2445
2021
Q4 		$385K Buy
8,984
+28
+0.3% +$1.46K ﹤0.01% 2494
2021
Q3 		$596K Buy
8,956
+3,894
+77% +$274K ﹤0.01% 2376
2021
Q2 		$372K Buy
5,062
+990
+24% +$65.4K ﹤0.01% 2394
2021
Q1 		$279K Buy
4,072
+2,162
+113% +$162K ﹤0.01% 2392
2020
Q4 		$128K Hold
1,910
– – ﹤0.01% 2520
2020
Q3 		$98K Buy
1,910
+219
+13% +$9.74K ﹤0.01% 2497
2020
Q2 		$64K Buy
1,691
+234
+16% +$8K ﹤0.01% 2653
2020
Q1 		$43K Buy
1,457
+768
+111% +$23.2K ﹤0.01% 2640
2019
Q4 		$24K Buy
689
+113
+20% +$2.76K ﹤0.01% 3129
2019
Q3 		$10K Buy
+576
New +$12.8K ﹤0.01% 3266

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's CSTL Position: Q1 2026 in Review

Legal & General Group reduced its Castle Biosciences (CSTL) stake by 22% in Q1 2026, selling an estimated $215K and leaving 23,184 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Legal & General Group first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $1.16M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Legal & General Group held 23,184 shares of Castle Biosciences worth $569K as of Q1 2026.
  • Legal & General Group sold 6,551 Castle Biosciences shares in Q1 2026, an estimated $215K.
  • Castle Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2324 holding.
  • Legal & General Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Legal & General Group's Castle Biosciences position peaked at $1.16M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.